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ABSTRACT 
Human paraoxonase 2 (PON2), which is a member of the paraoxonase family, possesses 
unique properties that distinguish it from PON1 and PON3. PON2 is ubiquitously expressed 
in many different tissue types and is highly expressed in the vital organs, such as the heart and 
lungs. Early research revealed that PON2 is exclusively intracellularly found, wherein it func-
tions as an anti-oxidative protein by reducing intracellular and local oxidative stress. Studies 
in the last five years have demonstrated that PON2 protects against atherosclerosis by pre-
venting low-density lipoprotein (LDL) oxidation, reversing the oxidation of mildly oxidised 
LDL, inhibiting monocyte chemotaxis, and increasing cholesterol efflux. Recently, emerging 
evidence has proposed that PON2 is an anti-atherosclerotic and may be associated with car-
diovascular disease (CVD). The number of investigations concerning the relationship between 
two common PON2 polymorphisms and CVD among different ethnic groups and regions is 
rapidly growing. Here, we briefly review the developments in PON2 research by focusing on 
past and recent findings. 
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INTRODUCTION 
The paraoxonase (PON) gene family 
consists of three highly conserved genes 
(PON1, PON2, and PON3) that are located 
in a cluster on chromosome 7q21.3-22.1 
and share a high degree of identity (La Du 
1996; Primo-Parmo et al., 1996). Studies in 
the last five years have focused on PON2 
because of its unique expression and local-
isation. In contrast to PON1 and PON3, 
which are exclusively found in the liver and 
are associated with HDL in the blood 
stream following secretion (Mackness et al., 
1996), PON2 is an intracellular protein that 
is widely expressed in many tissues, includ-
ing the liver, kidney, lung, heart, placenta, 
testis, stomach, spleen, pancreas, small in-
testine, skeletal muscle, artery wall cell, and 
macrophages (Ng et al., 2001, Levy et al., 
2007). Although PON2 has a similar struc-
ture to that of PON1 based on high amino 
acid sequence homology, PON2 possesses 
biological functions that are distinct from 
PON1. PON2 cannot hydrolyse organo-
phosphates, such as paraoxon, but, instead, 
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possesses hydrolase and lactonase activities 
(Draganov et al., 2005). Due to its anti-
oxidative and anti-atherosclerotic proper-
ties, which are similar to those of PON1, 
PON2 has become the subject of intense 
investigation. Both in vivo and in vitro 
models have revealed that PON2 prevents 
low-density lipoprotein (LDL) oxidation, 
reverses the oxidation of mildly oxidised 
LDL, inhibits oxidised LDL-induced 
monocyte chemotaxis (Ng et al., 2001), in-
creases cholesterol efflux (Ng et al., 2006a), 
and decreases the size of atherosclerotic 
lesions (Ng et al., 2006a, b). Furthermore, 
the anti-apoptotic capability of PON2 has 
been found to play a role in atherosclerotic 
protection (Horke et al., 2007). 
The human PON2 gene has two com-
mon polymorphisms, which result in amino 
acid substitutions of an alanine (A) or gly-
cine (G) at codon 148 (A148G) and a cys-
teine (C) or serine (S) at codon 311 
(C311S) (Mochizuki et al., 1998). As with 
PON1, inconsistent data have obfuscated 
the relationship between these two PON2 
polymorphisms and numerous pathophysi-
ological conditions. 
 
PON2 expression 
The human PON2 gene is located on the 
long arm of chromosome 7q21.3 and is ad-
jacent to PON gene family members PON1 
and PON3 (Primo-Parmo et al., 1996). 
Based on a phylogenetic analysis, PON2 is 
the oldest member of this gene family (Has-
sett et al., 1991; Draganov and La Du, 
2004). Approximately 70% and 65% of 
PON2 nucleotide and amino acid se-
quences, respectively, are similar to those 
of PON1 and PON3 (Primo-Parmo et al., 
1996). PON2 consists of nine exons that 
encode a 355-amino-acid protein of ap-
proximately 43 kDa in size. The PON2 
gene contains numerous transcription start 
sites and may be alternatively spliced, re-
sulting in several mRNA forms of PON2 
(Mochizuki et al., 1998); however, data re-
garding the cell types that express these 
various PON2 isoforms are lacking. Until 
now, only two PON2 protein isoforms of 40 
and 43 kDa in size have been commonly 
observed in a variety of cell types via im-
munoblotting with a specific anti-PON2 
antibody. These two isoforms are believed 
to be non-glycosylated and glycosylated, 
respectively, although the different func-
tions of these isoforms have not been re-
ported (Horke et al., 2007).  
The expression profile of PON2 demon-
strates two unique differences in compari-
son to those of PON1 and PON3. PON2 is 
widely expressed in many different tissues, 
and it was first detected in the brain, liver, 
kidney, and testis (Mochizuki et al., 1998). 
Ng and colleagues have detected higher 
levels of PON2 transcripts in the heart, 
lung, liver, placenta, and testis in compari-
son to other examined tissue types. PON2 
expression has also been observed in pri-
mary and immortalised human endothelial 
cells and in human arterial smooth muscle 
cells (Ng et al., 2001); however, the subcel-
lular localisation of PON2 remains ambigu-
ous. Although early studies have claimed 
that PON2 is an intracellular protein, evi-
dence obtained via confocal microscopy, 
biochemical cell fractionation, and the di-
gestion of outer membrane proteins has re-
vealed that PON2 is located in the nuclear 
envelope and the endoplasmic reticulum 
(ER) of EA.hy 926 cells (Horke et al., 
2007); however, PON2 mRNA and protein 
has recently been detected in the human 
gastrointestinal tract with decreasing ex-
pression levels from the upper to the lower 
levels of the tract (Levy et al., 2007). 
Moreover, PON2 localisation to the ER and 
release from the brush-border membrane in 
Caco-2 and HT-29 cells have been ob-
served (Shamir et al., 2005; Rothem et al., 
2007). These inconsistent findings imply 
that the cell type in which PON2 is ex-
pressed may influence the localisation of 
PON2 protein; Caco-2 and HT-29 cells are 
human adenocarcinomas of the colon, 
whereas EA.hy 926 cells are human vascu-
lar endothelial cells.  
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Modulation of PON2 
Most studies concerning the induction 
of PON2 expression by various stimuli 
have focused on oxidative stress because 
PON2 plays a role as an intracellular anti-
oxidant. Both in vitro and in vivo studies 
have demonstrated that PON2 expression 
and enzymatic activity increase during oxi-
dative stress. PON2 is up-regulated in re-
sponse to oxidative stress in different cell 
types (HepG2 cells and macrophages), 
animal models (mice fed high fat diets and 
apoE knockout mice), and in hypercholes-
terolemic patients (Shih et al., 1996, 1998; 
Forte et al., 2002; Rosenblat et al., 2003, 
2004). Mouse peritoneal macrophages 
(MPMs) that were treated with various 
agents that induce oxidative stress have 
demonstrated increased PON2 expression 
and lactonase activity (Rosenblat et al., 
2003). Shiner et al. have observed an ap-
proximate seven-fold increase in PON2 ex-
pression during monocyte/macrophage dif-
ferentiation that was dependent on the pres-
ence of nicotinamide adenine dinucleotide 
phosphate (NADPH), and this phenomenon 
was observed to correlate with an increase 
in cellular oxidative stress (Shiner et al., 
2004). In addition, PON2 has been found to 
be inactivated during low levels of oxida-
tive stress. Therefore, high levels of oxida-
tive stress may induce a cellular compensa-
tory mechanism that up-regulates PON2 
expression in macrophages (Shiner et al., 
2006).  
PON2 expression has also been investi-
gated in the context of common pathologi-
cal conditions, such as metabolic disorders 
that are characterised by an increase in oxi-
dative stress due to high cholesterol or glu-
cose levels. An in vivo chronic exposure of 
mice to high-cholesterol has been observed 
to cause an increase in hepatic PON2 
mRNA levels (Forte et al., 2002). Studies in 
J774A.1 mouse macrophages have provided 
similar results. Lysophosphatidylcholine 
(LPC) has been observed to increase PON2 
lactonase activity in J774A.1 cells (Rosen-
blat et al., 2006). In another in vivo study, 
human monocyte-derived macrophages 
(HMDMs) from hypercholesterolemic pa-
tients, which were subjected to oxidative 
stress, were observed to demonstrate less 
than half of the PON2 expression levels that 
were detected in HMDMs that had been 
isolated from control patients (Rosenblat et 
al., 2004). A similar result was obtained in 
diabetic mice, which demonstrated that the 
up-regulation of cellular PON2 in macro-
phages was associated with an increase in 
oxidative stress (Hayek et al., 2007). More-
over, increased PON2 expression has also 
been observed in response to pharmaceuti-
cal compounds, such as the lipid lowering 
agent atorvastatin and the anti-diabetic drug 
rosiglitazone, among other agents. Atorvas-
tatin or rosiglitazone can up-regulate PON2 
expression, and elevated PON2 activity has 
been observed to result in the reduction of 
cellular oxidative stress in patient HMDMs 
and mouse macrophages, respectively 
(Rosenblat et al., 2004; Shiner et al., 
2007b). In contrast, proinflammatory 
agents, such as lipopolysaccharide (LPS), 
have been found to decrease PON2 expres-
sion in Caco-2/15 cells and in the human 
intestine (Precourt et al., 2009).  
Studies investigating dietary compo-
nents that modulate PON2 expression are 
currently underway. Pomegranate juice (PJ) 
and extracts from different parts of the plant 
significantly increase PON2 expression and 
lactonase activity in J774A.1 cells and in 
MPMs that have been isolated from athero-
sclerotic apolipoprotein E-deficient mice 
(Shiner et al., 2007a; Aviram et al., 2008). 
Supplementation with quercetin or the me-
thylated quercetin derivative isohamnetin 
has been found to up-regulate PON2 
mRNA and protein levels in the RAW264.7 
murine macrophage cell line; however, 
studies in humans have provided contrast-
ing results. Quercetin supplementation in 
human volunteers had no affect on PON2 
mRNA levels in human monocytes 
(Boesch-Saadatmandi et al., 2009). 
Elucidation of the mechanism that is re-
sponsible for the modulation of PON2 re-
quires further investigation, although recent 
findings have demonstrated that unfolded 
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proteins in the endoplasmic reticulum (ER) 
induce PON2 expression at both the pro-
moter and protein levels in the three as-
sessed cell lines (human umbilical vein en-
dothelial cell-derived EA.hy 926 cells, pri-
mary human coronary artery smooth muscle 
cells [SMCs], and primary human aortic 
adventitial fibroblasts [AoAFs]) (Horke et 
al., 2007). Investigations of the signalling 
pathways of PON2 modulation have re-
vealed that it may involve the urokinase 
plasminogen activator (uPA), extracellular 
signal-regulated kinase (ERK1/2), NADPH 
oxidase (NOX), phosphatidylinositol 3-
kinase (PI3K), platelet-derived growth fac-
tor receptor-β (PDGFR-β), the tyrosine 
kinase cascade, the NF-kappa B pathway 
and lipid peroxidation, PPARγ, and AP-1 
(Shiner et al., 2007a, b; Fuhrman et al., 
2008, 2009; Precourt et al., 2009). Re-
cently, a functional study of the PON2 
promoter revealed a putative sterol regula-
tory binding protein-2 (SREBP-2) DNA 
element that is located between -593 bp and 
-575 bp of the PON2 promoter that may 
play a major role in PON2 regulation 
(Fuhrman et al., 2009; Lim and Kim, 2009).  
 
Role of PON2 in human diseases 
As with other PON family members, 
when PON2 was first discovered, the spe-
cific substrates and exact physiological 
functions of this protein were uncertain; 
however, the high structural similarity of 
PON2 to other members of the PON family 
have indicated that it might possess an ac-
tivity that is analogous to those of PON1 
and PON3. Like PON1 and PON3, PON2 
very efficiently metabolises 5-hydroxy-
eicosatetraenoic acid 1,5-lactone and 4-
hydroxy-docosahexaenoic acid, which are 
the oxidation products of arachidonic acid 
and docosahexaenoic acid, respectively, 
and may also be endogenous substrates for 
PON2 (Draganov et al., 2005); however, 
unlike PON1, PON2 is incapable of hydro-
lysing organophosphates, such as paraoxon, 
although it has been demonstrated to pos-
sess a greater lactonase activity in compari-
son to those of PON1 and PON3 when di-
hydrocoumarin and some arylesters are 
used as substrates (Rosenblat et al., 2003; 
Draganov et al., 2005). Although PON2 has 
a lower anti-oxidative capacity than PON1 
(Draganov et al., 2005), several recent in-
vestigations of this protein have been con-
ducted due to its high expression level and 
widespread localisation. Studies using ei-
ther purified PON2 or PON2-over-
expressing cells have provided similar re-
sults. Exposure of PON2-overexpressing 
Hela cells to hydrogen peroxide or oxidised 
phospholipids has been observed to de-
crease intracellular oxidative stress by re-
ducing the levels of reactive oxygen species 
(ROS), preventing LDL lipid peroxidation, 
reversing the oxidation of mildly oxidised 
LDL (MM-LDL), and inhibiting the ability 
of MM-LDL to induce monocyte chemo-
taxis (Ng et al., 2001). Treatment of mouse 
macrophages with purified recombinant 
PON2 has been shown to prevent LDL oxi-
dation (Rosenblat et al., 2003).  
Studies in animals have also provided 
similar results. PON2 has been shown to 
provide protection against HDL and LDL 
oxidation and inhibit monocyte transmigra-
tion in response to LDL oxidation in PON2-
knockout (PON2KO) mice (Ng et al., 
2006a). Interestingly, these PON2 knockout 
mice demonstrate an increased number of 
foam cells and lipid droplets and develop 
significantly larger atherosclerotic lesions 
in comparison to their wild-type counter-
parts (Ng et al., 2006b). In contrast, the 
atherosclerotic lesions in AdPON2-over-
expressing apoE-deficient mice (apoE-/-) 
are significantly smaller than those in their 
wild-type counterparts. Furthermore, serum 
obtained from AdPON2-treated mice con-
tains significantly lower levels of lipid hy-
droperoxides and demonstrates an enhanced 
capacity to induce cholesterol efflux from 
cholesterol-loaded macrophages. In addi-
tion to increasing cholesterol efflux, PON2 
has been found to inhibit triglyceride (TG) 
biosynthesis and microsomal diacylglycerol 
acyltransferase 1 (DAGT1) activity, result-
ing in a decreased accumulation of TG in 
macrophages of PON2-deficient mice 
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(Meilin et al., 2009; Rosenblat et al., 2009). 
PON2 has been proposed to function as an 
antiapoptotic factor in atherosclerosis. 
PON2 overexpression in EA.hy 926 cells 
was found to protect the endoplasmic re-
ticulum against oxidative stress-induced 
apoptosis by specifically preventing the 
generation of superoxide radicals at the in-
ner mitochondrial membrane (Horke et al., 
2008; Altenhöfer et al., 2010). Currently, 
based on several lines of evidence, the anti-
atherosclerotic effects of PON2 have been 
clearly delineated. 
 
Association of PON2 polymorphisms with 
human diseases 
Several polymorphisms in the PON2 
gene have been reported to date; however, 
only two common PON2 polymorphisms 
play a prominent role in pathophysiological 
conditions: codon 148 is either an alanine 
or a glycine (A148G), and codon 311 is ei-
ther a cysteine or a serine (C311S) (Mochi-
zuki et al., 1998). Many studies have inves-
tigated the PON2 gene polymorphism fre-
quencies, and the results therein have re-
vealed variations in different ethnic groups 
as shown in Table 1. Based on current evi-
dence, most populations carry the A allele 
at codon 148 and the S allele at codon 311.  
 
Oxidative stress is believed to be in-
volved in human diseases. Because of the 
anti-oxidative and anti-atherosclerotic po-
tential of PON2, there has been interest in 
examining the association of PON2 with 
CVD and other pathological disorders, such 
as diabetic mellitus, Alzheimer’s disease, 
and sporadic amyotrophic lateral sclerosis 
(ALS); however, most studies have investi-
gated the associations of PON2 polymor-
phisms with these diseases rather than the 
relationship between PON2 activity and 
disease. This may be because the true bio-
logical substrate of PON2 remains un-
known. Currently, the activity of PON2 is 
determined from the hydrolysis of dihydro-
coumarin (DHC), and the appropriateness 
of this substrate is still subject to debate. 
Therefore, studies investigating the associa-
tion of PON2 activity with diseases have 
been scarce because of the lack of well-
established methods. Instead, most studies 
emphasise the association of PON2 poly-
morphisms with various pathologies and 
diseases in different ethnic groups as shown 
in Table 2. The resulting data have been 
inconsistent because of the variations in dif-
ferent experimental conditions, ethnicities, 
and geographical locations. Hence, further 
investigations are required. 
 
 
 
Table 1: Gene distributions of PON2 at codons 148 and 311 
 
Allele frequencies at 
codon 148 
Allele frequencies at 
codon 311 
Population (n) 
A allele G allele C allele S allele 
Ref. 
Brazil (376) 0.6 0.4 0.29 0.71 Oliveira et al., 2004 
Canada (324) 0.76 0.24 - - McKeown-Eyssen et al., 
2004 
China (475) 0.826 0.174 0.173 0.827 Wang et al., 2003a 
United Kingdom 
(405) 
0.73 0.27 0.26 0.74 Pasdar et al., 2006 
Israel (193) - - 0.158 0.842 Karban et al., 2007 
Italy (273) - - 0.198 0.802 Martinelli et al., 2004 
Japan (2,210) - - 0.198 0.802 Yamada et al., 2003 
Korea (988) 0.7825 0.2175 0.2175 0.7825 Shin, 2009 
Pakistan (370) 0.51 0.49 0.612 0.388 Saeed et al., 2007 
Poland (437) - - 0.24 0.76 Slowik et al., 2007 
United States 
(2,553) 
0.766 0.234 - - Ranade et al., 2005 
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Table 2: Association between PON2 polymorphisms and various diseases 
 
Polymorphism Disease Population Ref. 
associated with a risk for coro-
nary artery disease (CAD) 
Asian Indians 
 
Taiwan 
 
WISE study 
group* 
 
Chinese 
 
Iranians 
Sanghera et al., 1998 
 
Pan et al., 2002 
 
Chen et al., 2003 
 
 
Qin et al., 2006 
 
Jalilian et al., 2008 
associated with coronary heart 
disease (CHD) 
Chinese Han 
women 
Su et al., 2005 
not associated with CHD Chinese  
 
NPHSII** 
 
Meta-analysis of 
43 studies 
Wang et al., 2003a 
 
Robertson et al., 2003 
 
Wheeler et al., 2004  
associated with acute myocar-
dial infarction (AMI) 
Italians Marchegiani et al., 2009  
 
associated with myocardial in-
farction (MI) in smokers but not 
in non-smokers 
Verona Heart 
Project 
Martinelli et al., 2004  
not associated with AMI Spanish 
autonomous 
regions 
Guxens et al., 2008 
associated with type 2 diabetes 
with ischemic stroke 
Chinese  Wang et al., 2003b  
associated with the severity of 
ischemic stroke 
 
 
Greece 
 
 
Polish 
Lazaros et al., 2010  
 
 
Slowik et al., 2007  
not associated with ischemic 
stroke 
Japanese 
 
CARE trial*** 
 
Chinese Han 
Imai et al., 2000  
 
Ranade et al., 2005  
 
Xu et al., 2005  
associated with type 1 and 2 
diabetes 
Caucasian origin Mackness et al., 2005  
associated with glycemic control 
in type 2 diabetes with retinopa-
thy 
England Mackness et al., 2000  
associated with nephropathy in 
type 2 diabetes 
Swiss  Pinizzotto et al., 2001  
associated with microalbuminu-
ria in type 1 diabetes 
Caucasians  Kao et al., 2002  
311 
not associated with diabetic 
nephropathy 
Russians  Voron’ko et al., 2005  
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Table 2 (cont.): Association between PON2 polymorphisms and various diseases 
 
Polymorphism Disease Population Ref. 
associated with Alzheimer’s dis-
ease and vascular dementia 
Caucasian  
probands 
Janka et al., 2002 
associated with sporadic late-
onset Alzheimer’s disease 
Chinese  Shi et al., 2004  
associated with sporadic amyo-
trophic lateral sclerosis (ALS) 
Polish 
 
North 
Americans and 
Europeans 
Slowik et al., 2006  
 
Valdmanis et al., 2008  
not associated with sporadic 
ALS 
Meta-analysis Wills et al., 2009  
associated with familial hyper-
cholesterolemia (FH) sympto-
matic 
Caucasians Leus et al., 2009  
associated with total cholesterol 
and LDL 
Southwestern 
Koreans 
Shin, 2009 
not associated with open-angle 
glaucoma (OAG) 
Japanese Inagaki et al., 2006 
 
associated with preterm neonate
 
Chinese  
 
Chinese 
Liang et al., 2002a  
 
Chen et al., 2004  
not associated with risk for CAD Taiwanese  Pan et al., 2002  
not associated with stroke Chinese Han Xu et al., 2008  
not associated with risk factors 
for CHD 
Chinese Chi et al., 2006  
associated with total cholesterol 
and LDL 
 
 
 
 
 
Canada  
(Oji-Cree) 
 
Southwestern 
Koreans 
 
Brazilians 
Hegele et al., 1998  
 
 
Shin, 2009  
 
 
Olivera et al., 2004  
associated with fasting plasma 
glucose in type 2 diabetes 
Canada  
(Oji-Cree) 
Hegele et al., 1997  
not associated with plasma  
glucose 
Alberta  
Hutterites 
Boright et al., 1998  
associated with type 2 diabetes 
with renal disease 
Americans Thameem et al., 2009  
not associated with diabetic 
nephropathy 
Russians  Voron’ko et al., 2005  
associated with low birth weight South Asian  
Origin 
Busch et al., 1999  
148 
associated with preterm neonate Chinese 
 
Chinese 
Wu et al., 2003  
 
Liang et al., 2002b  
* Women’s Ischemia Syndrome Evaluation (WISE) study 
** Northwick Park Heart Study II 
*** Cholesterol and Recurrent Events (CARE) trial 
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CONCLUSION 
The anti-oxidative and antiatherogenic 
activities of PON2 have been well docu-
mented over the past five years; however, 
an identification of the location, biological 
functions, and activity of PON2 is required 
for further investigation. It would be of in-
terest to explore PON2 within the context 
of other disorders, such as cancer or abnor-
malities in metabolic consumption, because 
of its anti-oxidative role, intracellular loca-
tion, and expression in most organs at high 
metabolic rates and incidence in relation to 
distinct types of cancers, such as those as-
sociated with the lung, liver, testis, heart, 
and placenta. An investigation of the ex-
ogenous modulation of PON2, especially by 
nutrition and pharmacological means, has 
only recently been initiated; hence, many 
issues and questions still remain. Future 
studies should provide substantial evidence 
on both PON2 modulation and the mecha-
nisms by which chemicals may modulate 
PON2 expression. Most studies have at-
tempted to relate DNA sequence variants in 
the PON2 locus to the risk for CVD and 
other diseases. The controversial findings 
that have been obtained for the two com-
mon PON2 polymorphisms that are associ-
ated with CVD have led to equivocal con-
clusions. The differences in these findings 
may derive from individual susceptibilities 
that are related to many other factors that 
are associated with ethnic background and 
life style.  
 
REFERENCES 
Altenhöfer S, Witte I, Teiber JF, Wilgenbus 
P, Pautz A, Li H, et al. One enzyme, two 
functions: PON2 prevents mitochondrial 
superoxide formation and apoptosis inde-
pendent from its lactonase activity. J Biol 
Chem 2010;285:24398-403. 
 
Aviram M, Volkova N, Coleman R, Dreher 
M, Reddy MK, Ferreira D, et al. Pomegran-
ate phenolics from the peels, arils, and 
flowers are antiatherogenic: studies in vivo 
in atherosclerotic apolipoprotein E-deficient 
(E0) mice and in vitro in cultured macro-
phages and lipoproteins. J Agric Food 
Chem 2008;56:1148-57.  
 
Boesch-Saadatmandi C, Pospissil RT, 
Graeser AC, Canali R, Boomgaarden I, Do-
ering F, et al. Effect of quercetin on 
paraoxopnase 2 levels in RAW264.7 
macrophages and in human monocytes-role 
of quercetin metabolism. Int J Mol Sci 
2009;10:4168-77.  
 
Boright AP, Connelly PW, Brunt JH, 
Scherer SW, Tsui LC, Hegele RA. Genetic 
variation in paraoxonase-1 and paraoxo-
nase-2 is associated with variation in 
plasma lipoproteins in Alberta Hutterites. 
Atherosclerosis 1998;139:131-6.  
 
Busch CP, Ramdath DD, Ramsewak S, He-
gele RA. Association of PON2 variation 
with birth weight in Trinidadian neonates of 
South Asian ancestry. Pharmacogenetics 
1999;9:351-6. 
 
Chen D, Hu Y, Chen C, Yang F, Fang Z, 
Wang L, et al. Polymorphisms of the 
paraoxonase gene and risk of preterm deliv-
ery. Epidemiology 2004;15:466-70. 
 
Chen Q, Reis SE, Kammerer CM, McNa-
mara DM, Holubkov R, Sharaf BL, et al. 
Association between the severity of an-
giographic coronary artery disease and 
paraoxonase gene polymorphisms in the 
National Heart, Lung, and Blood Institute-
sponsored Women's Ischemia Syndrome 
Evaluation (WISE) study. Am J Hum Genet 
2003;72:13-22.  
 
EXCLI Journal 2010;9:159-172 – ISSN 1611-2156 
Received: October 15, 2010, accepted: November 23, 2010, published: November 26, 2010 
 
167 
Chi DS, Liang WH, Ma J, Xia M, Hou MJ, 
Wang Q, et al. Study of the association be-
tween paraoxonase1 55 Met/Leu, paraoxo-
nase2 148/Gly and manganese superoxide 
dismutase (MnDOD) 9 Ala/Val genetic 
polymorphisms and coronary heart disease. 
Zhonghua Xin Xue Guan Bing Za Zhi 
2006:27:808-13. 
 
Draganov DI, La Du BN. Pharmacogenetics 
of paraoxonases: a brief review. Naunyn 
Schmiedeberg's Arch Pharmacol 2004;369: 
78-88. 
 
Draganov DI, Teiber JE, Speelman A, 
Osawa Y, Sunahara R, La Du BN. Human 
paraoxonases (PON1, PON2, and PON3) 
are lactonases with overlapping and distinct 
substrate specificities. J Lipid Res 2005;46: 
1239-47. 
 
Forte TM, Subbanagounder G, Berliner JA, 
Blanche PJ, Clermont AO, Jia Z, et al. Al-
tered activities of anti-atherogenic enzymes 
LCAT, paraoxonase, and platelet-activating 
factor acetylhydrolase in atherosclerosis-
susceptible mice. J Lipid Res 2002;43:477-
85. 
 
Fuhrman B, Khateeb J, Shiner M, Nitzan O, 
Karry R, Volkova N, et al. Urokinase plas-
minogen activator upregulates paraoxo-
nase2 expression in macrophages via an 
NADPH oxidase-dependent mechanism. 
Arterioscler Thromb Vasc Biol 2008;28: 
1361-7.  
 
Fuhrman B, Gantman A, Khateeb J, Volk-
ova N, Horke S, Kiyan J, et al. Urokinase 
activates macrophage PON2 gene transcrip-
tion via the PI3K/ROS/MEK/SREBP-2 sig-
nalling cascade mediated by the PDGFR-
beta. Cardiovasc Res 2009;84:145-54. 
 
Guxens M, Tomás M, Elosua R, Aldasoro 
E, Segura A, Fiol M, et al. Association be-
tween paraoxonase-1 and paraoxonase-2 
polymorphisms and the risk of acute myo-
cardial infarction. Rev Esp Cardiol 2008; 
61:269-75. 
Hassett C, Richter RJ, Humbert R, Chapline 
C, Crabb JW, Omiecinski CJ, et al. Charac-
terisation of cDNA clones encoding rabbit 
and human serum paraoxonase: the mature 
protein retains its signal sequence. Bio-
chemistry 1991;30:10141-9. 
 
Hayek T, Kaplan M, Kerry R, Aviram M. 
Macrophage NADPH oxidase activation, 
impaired cholesterol fluxes, and increased 
cholesterol biosynthesis in diabetic mice: a 
stimulatory role for D-glucose. Atheroscle-
rosis 2007;195:277-86.  
 
Hegele RA, Connelly PW, Scherer SW, 
Hanley AJ, Harris SB, Tsui LC, et al. 
Paraoxonase-2 gene (PON2) G148 variant 
associated with elevated fasting plasma 
glucose in noninsulin-dependent diabetes 
mellitus. J Clin Endocrinol Metab 1997;82: 
3373-7.  
 
Hegele RA, Harris SB, Connelly PW, Han-
ley AJ, Tsui LC, Zinman B, et al. Genetic 
variation in paraoxonase-2 is associated 
with variation in plasma lipoproteins in Ca-
nadian Oji-Cree. Clin Genet 1998;54:394-9. 
 
Horke S, Witte I, Wilgenbus P, Krüger M, 
Strand D, Förstermann U. Paraoxonase-2 
reduces oxidative stress in vascular cells 
and decreases endoplasmic reticulum stress-
induced caspase activation. Circulation 
2007;115:2055-64. 
 
Horke S, Witte I, Wilgenbus P, Altenhöfer 
S, Krüger M, Li H, et al. Protective effect 
of paraoxonase-2 against endoplasmic re-
ticulum stress-induced apoptosis is lost 
upon disturbance of calcium homoeostasis. 
Biochem J 2008;416:395-405.  
 
Imai Y, Morita H, Kurihara H, Sugiyama T, 
Kato N, Ebihara A, et al. Evidence for as-
sociation between paraoxonase gene poly-
morphisms and atherosclerotic diseases. 
Atherosclerosis 2000;149:435-42.  
 
EXCLI Journal 2010;9:159-172 – ISSN 1611-2156 
Received: October 15, 2010, accepted: November 23, 2010, published: November 26, 2010 
 
168 
Inagaki Y, Mashima Y, Funayama T, 
Ohtake Y, Fuse N, Yasuda N, et al. 
Paraoxonase 1 gene polymorphisms influ-
ence clinical features of open-angle glau-
coma. Graefes Arch Clin Exp Ophthalmol 
2006;244:984-90. 
 
Jalilian A, Javadi E, Akrami M, Fakhrzadeh 
H, Heshmat R, Rahmani M, et al. Associa-
tion of Cys311Ser polymorphism of 
paraoxonase-2 gene with the risk of coro-
nary artery disease. Arch Iranian Med 
2008;11:544-9. 
 
Janka Z, Juhász A, Rimanóczy AA, Boda 
K, Márki-Zay J, Kálmán J. Codon 311 (Cys 
Ser) polymorphism of paraoxonase-2 gene 
is associated with apolipoprotein E4 allele 
in both Alzheimer's and vascular dementias. 
Mol Psychiatry 2002;7:110-2. 
 
Kao Y, Donaghue KC, Chan A, Bennetts 
BH, Knight J, Silink M. Paraoxonase gene 
cluster is a genetic marker for early mi-
crovascular complications in type 1 diabe-
tes. Diabet Med 2002;19:212-5.  
 
Karban A, Hartman C, Eliakim R, Water-
man M, Nesher S, Barnett-Griness O, et al. 
Paraoxonase (PON)1 192R allele carriage is 
associated with reduced risk of inflamma-
tory bowel disease. Dig Dis Sci 2007;52: 
2707-15. 
 
La Du BN. Structural and functional diver-
sity of paraoxonase. Nat Med 1996;2:1186-
7. 
 
Lazaros L, Markoula S, Kyritsis A, Geor-
giou I. Paraoxonase gene polymorphisms 
and stroke severity. Eur J Neurol 2010;17: 
757-9. 
 
Leus FR, Zwart M, Kastelein JJ, Voorbij 
HA. PON2 gene variants are associated 
with clinical manifestations of cardiovascu-
lar disease in familial hypercholesterolemia 
patients. Atherosclerosis 2001;154:641-9. 
 
Levy E, Trudel K, Bendayan M, Seidman 
E, Delvin E, Elchebly M, et al. Biological 
role, protein expression, subcellular local-
ization, and oxidative stress response of 
paraoxonase 2 in the intestine of humans 
and rats. Am J Physiol Gastrointest Liver 
Physiol 2007;293:G1252-61. 
 
Liang HY, Wu BY, Chen DF, Yang F, Hu 
HY, Chen L, et al. Association of CYP2E1 
of PON2 311 polymorphisms in neonates 
with preterm. Yi Chuan Xue Bao 2002a;29: 
847-53. 
 
Liang HY, Wu BY, Chen DF, Yang F, Hu 
HY, Chen L, et al. Association of PON2 
gene polymorphisms in neonates with pre-
term. Yi Chuan Xue Bao 2002b;24:515-8. 
 
Lim JA, Kim SH. Transcriptional activation 
of an anti-oxidant mouse Pon2 gene by dex-
amethasone. BMB Rep 2009;42:421-6.  
 
Mackness B, Durrington PN, Abuashia B, 
Boulton AJ, Mackness MI. Low paraoxo-
nase activity in type II diabetes mellitus 
complicated by retinopathy. Clin Sci (Lond) 
2000;98:355-63. 
 
Mackness B, McElduff P, Mackness MI. 
The paraoxonase-2-310 polymorphism is 
associated with the presence of microvascu-
lar complications in diabetes mellitus. J In-
tern Med 2005;258:363-8. 
 
Mackness MI, Mackness B, Durrington PN, 
Connelly PW, Hegele RA. Paraoxonase: 
biochemistry, genetics and relationship to 
plasma lipoproteins. Curr Opin Lipidol 
1996;7:69-76. 
 
Marchegiani F, Spazzafumo L, Provinciali 
M, Cardelli M, Olivieri F, Franceschi C, et 
al. Paraoxonase2 C311S polymorphism and 
low levels of HDL contribute to a higher 
mortality risk after acute myocardial infarc-
tion in elderly patients. Mol Genet Metab 
2009;98:314-8.  
 
EXCLI Journal 2010;9:159-172 – ISSN 1611-2156 
Received: October 15, 2010, accepted: November 23, 2010, published: November 26, 2010 
 
169 
Martinelli N, Girelli D, Olivieri O, Stranieri 
C, Trabetti E, Pizzolo F, et al. Interaction 
between smoking and PON2 Ser311Cys 
polymorphism as a determinant of the risk 
of myocardial infarction. Eur J Clin Invest 
2004;34:14-20.  
 
McKeown-Eyssen G, Baines C, Cole D, 
Riley N, Tyndale RF, Marshall L, et al. 
Case-control study of genotypes in multiple 
chemical sensitivity: CYP2D6, NAT1, 
NAT2, PON1, PON2 and MTHFR. Int J 
Epidemiol 2004;33:971-8. 
 
Meilin E, Aviram M, Hayek T. 
Paraoxonase 2 (PON2) decreases high glu-
cose-induced macrophage triglycerides 
(TG) accumulation, via inhibition of 
NADPH-oxidase and DGAT1 activity: 
Studies in PON2-deficient mice. Athero-
sclerosis 2009;208:390-5.  
 
Mochizuki H, Scherer SW, Xi T, Nickle 
DC, Majer M, Huizenga JJ, et al. Human 
PON2 gene at 7q21.3: cloning, multiple 
mRNA forms, and missense polymor-
phisms in the coding sequence. Gene 
1998;213:149-57. 
 
Ng CJ, Wadleigh DJ, Gangopadhyay A, 
Hama S, Grijalva VR, Navab M, et al. 
Paraoxonase-2 is a ubiquitously expressed 
protein with antioxidant properties and is 
capable of preventing cell-mediated oxida-
tive modification of low density lipoprotein. 
J Biol Chem 2001;276:44444-9. 
 
Ng CJ, Hama SY, Bourquard N, Navab M, 
Reddy ST. Adenovirus mediated expression 
of human paraoxonase 2 protects against 
the development of atherosclerosis in apoli-
poprotein E-deficient mice. Mol Genet Me-
tab 2006a;89:368-73.  
 
Ng CJ, Bourquard N, Grijalva V, Hama S, 
Shih DM, Navab M, et al. Paraoxonase-2 
deficiency aggravates atherosclerosis in 
mice despite lower apolipoproteinB-
containing lipoproteins: anti-atherogenic 
role for paraoxonase-2. J Biol Chem 
2006b;281:29491-500. 
 
Oliveira SA, Mansur AP, Ribeiro CC, Ra-
mires JA, Annichino-Bizzacchi JM. PON1 
M/L55 mutation protects high-risk patients 
against coronary artery disease. Int J Car-
diol 2004;94:73-7. 
 
Pan JP, Lai ST, Chiang SC, Chou SC, 
Chiang AN. The risk of coronary artery dis-
ease in population of Taiwan is associated 
with Cys-Ser 311 polymorphism of human 
paraoxonase (PON)-2 gene. Zhonghua Yi 
Xue Za Zhi (Taipei) 2002;65:411-2. 
 
Pasdar A, Ross-Adams H, Cumming A, 
Cheung J, Whalley L, St Clair D, et al. 
Paraoxonase gene polymorphisms and hap-
lotype analysis in a stroke population. BMC 
Med Genet 2006;7:28. 
 
Pinizzotto M, Castillo E, Fiaux M, Temler 
E, Gaillard RC, Ruiz J. Paraoxonase2 
polymorphisms are associated with neph-
ropathy in type II diabetes. Diabetologia 
2001;44:104-7. 
 
Precourt LP, Seidman E, Delvin E, Amre 
D, Deslandres C, Dominguez M, et al. 
Comparative expression analysis reveals 
differences in the regulation of intestinal 
paraoxonase family members. Int J Bio-
chem Cell Biol 2009;41:1628-37. 
 
Primo-Parmo SL, Sorenson RC, Teiber J, 
La Du BN. The human serum paraoxonase/ 
arylesterase gene (PON1) is one member of 
a multigene family. Genomics 1996;33: 
498-507.  
 
EXCLI Journal 2010;9:159-172 – ISSN 1611-2156 
Received: October 15, 2010, accepted: November 23, 2010, published: November 26, 2010 
 
170 
Qin Q, Li YL, Zhao FM, Wang H, Li Y, 
Cui RZ, et al. Association of paraoxonase 
polymorphisms and serum homocysteine 
thiolactone complex with coronary heart 
disease. Zhonghua Xin Xue Guan Bing Za 
Zhi 2006;34:803-7.  
 
Ranade K, Kirchgessner TG, Iakoubova 
OA, Devlin JJ, DelMonte T, Vishnupad P, 
et al. Evaluation of the paraoxonases as 
candidate genes for stroke: Gln192Arg 
polymorphism in the paraoxonase 1 gene is 
associated with increased risk of stroke. 
Stroke 2005;36:2346-50.  
 
Robertson KS, Hawe E, Miller GJ, Talmud 
PJ, Humphries SE. Northwick Park Heart 
Study II. Human paraoxonase gene cluster 
polymorphisms as predictors of coronary 
heart disease risk in the prospective North-
wick Park Heart Study II. Biochim Biophys 
Acta 2003;1639:203-12.  
 
Rosenblat M, Draganov D, Watson CE, 
Bisgaier CL, La Du BN, Aviram M.  Mouse 
macrophage paraoxonase 2 activity is in-
creased whereas cellular paraoxonase 3 ac-
tivity is decreased under oxidative stress. 
Arterioscler Thromb Vasc Biol 2003;23: 
468-74.  
 
Rosenblat M. Hayek T, Hussein K, Aviram 
M. Decreased macrophage paraoxonase 2 
expression in patients with hypercholes-
terolemia is the result of their increased cel-
lular cholesterol content: effect of atorvas-
tatin therapy. Arterioscler Thromb Vasc 
Biol 2004;24:175-80. 
 
Rosenblat M, Oren R, Aviram M. Lyso-
phosphatidylcholine (LPC) attenuates 
macrophage-mediated oxidation of LDL. 
Biochem Biophys Res Commun 2006;344: 
1271-7.  
 
Rosenblat M, Coleman R, Reddy ST, Avi-
ram M. Paraoxonase 2 attenuates macro-
phage triglyceride accumulation via inhibi-
tion of diacylglycerol acyltransferase 1 the 
rate limiting enzyme in triglycerides bio-
synthesis. J Lipid Res 2009;50:870-9.  
 
Rothem L, Hartman C, Dahan A, Lachter J, 
Eliakim R, Shamir R. Paraoxonases are as-
sociated with intestinal inflammatory dis-
eases and intracellularly localized to the 
endoplasmic reticulum. Free Radic Biol 
Med 2007;43:730-9. 
 
Saeed M, Iqbal P, Yousuf FA, Perveen S, 
Shafiq M, Sajid J, et al. Interactions and 
associations of paraoxonase gene cluster 
polymorphisms with myocardial infarction 
in a Pakistani population. Clin Genet 2007; 
71:238-47. 
 
Sanghera DK, Aston CE, Saha N, Kamboh 
MI. DNA polymorphisms in two paraoxo-
nase genes (PON1 and PON2) are associ-
ated with the risk of coronary heart disease. 
Am J Hum Genet 1998;62:36-44. 
 
Shamir R, Hartman C, Karry R, Pavlotzky 
E, Eliakim R, Lachter J, et al. Paraoxonases 
(PONs) 1, 2, and 3 are expressed in human 
and mouse gastrointestinal tract and in 
Caco-2 cell line: selective secretion of 
PON1 and PON2. Free Radic Biol Med 
2005;39:336-44. 
 
Shi J, Zhang S, Tang M, Liu X, Li T, Han 
H, et al. Possible association between 
Cys311Ser polymorphism of paraoxonase 2 
gene and late-onset Alzheimer's disease in 
Chinese. Mol Brain Res 2004;120:201-4.  
 
Shih DM, Gu L, Hama S, Xia Y-R, Navab 
M, Fogelman AM, et al. Genetic-dietary 
regulation of serum paraoxonase expression 
and its role in atherogenesis in a mouse 
model. J Clin Invest 1996;97:1630–9. 
 
EXCLI Journal 2010;9:159-172 – ISSN 1611-2156 
Received: October 15, 2010, accepted: November 23, 2010, published: November 26, 2010 
 
171 
Shih DM, Gu LY, Xia R, Navab M, Li W, 
Hama S, et al. Mice lacking serum paraoxo-
nase are susceptible to organophosphate 
toxicity and atherosclerosis. Nature 1998; 
394:284-7. 
 
Shin BS. Paraoxonase gene polymorphism 
in south-western Korean population. J Ko-
rean Med Sci 2009;24:561-6.  
 
Shiner M, Fuhrman B, Aviram M. 
Paraoxonase 2 (PON2) expression is 
upregulated via a reduced-nicotinamide-
adenine-dinucleotide-phosphate (NADPH)-
oxidase-dependent mechanism during 
monocytes differentiation into macro-
phages. Free Radic Biol Med 2004;37: 
2052-63. 
 
Shiner M, Fuhrman B, Aviram M. A bi-
phasic U-shape effect of cellular oxidative 
stress on the macrophage anti-oxidant 
paraoxonase 2 (PON2) enzymatic activity. 
Biochem Biophys Res Commun 2006;349: 
1094-9. 
 
Shiner M, Fuhrman B, Aviram M. Macro-
phage paraoxonase 2 (PON2) expression is 
up-regulated by pomegranate juice phenolic 
anti-oxidants via PPAR gamma and AP-1 
pathway activation. Atherosclerosis 2007a; 
195:313-21. 
 
Shiner M, Fuhrman B, Aviram M. Macro-
phage paraoxonase2 (PON2) expression is 
upregulated by unesterified cholesterol 
through activation of the phosphatidylinosi-
tol 3-kinase (PI3K) pathway. Biol Chem 
2007b;388:1353-8. 
 
Slowik A, Tomik B, Wolkow PP, Partyka 
D, Turaj W, Marecki MT, et al. Paraoxo-
nase gene polymorphisms and sporadic 
ALS. Neurology 2006;67:766-70. 
 
Slowik A, Wloch D, Szermer P, Wolkow P, 
Malecki M, Pera J, et al. Paraoxonase 2 
gene C311S polymorphism is associated 
with a risk of large vessel disease stroke in 
a Polish population. Cerebrovasc Dis 2007; 
23:395-400.  
 
Su SY, Chen JH, Huang JF, Wang XL, 
Zhao JG, Shen Y, et al. Paraoxonase gene 
cluster variations associated with coronary 
heart disease in Chinese Han women. Chin 
Med J (Engl) 2005;118:1167-74. 
 
Thameem F, He X, Voruganti VS, Nath 
SD, Fanti P, Blangero J, et al. Evaluation of 
polymorphisms in paraoxonase 2 (PON2) 
gene and their association with cardiovas-
cular-renal disease risk in Mexican Ameri-
cans. Kidney Blood Press Res 2009;32:200-
4.  
 
Valdmanis PN, Kabashi E, Dyck A, Hince 
P, Lee J, Dion P, et al. Association of 
paraoxonase gene cluster polymorphisms 
with ALS in France, Quebec, and Sweden. 
Neurology 2008;71:514-20. 
 
Voron'ko OE, Iakunina N, Shestakova MV, 
Zotova EV, Chugunova EV, Shamkhalova 
M, et al. A search for association between 
the polymorphic markers of PON1 and 
PON2 genes and diabetic nephropathy in 
patients with type I diabetes mellitus. Ge-
netika 2005;41:844-9. 
 
Wang X, Fan Z, Huang J, Su S, Yu Q, Zhao 
J, et al. Extensive association analysis be-
tween polymorphisms of PON gene cluster 
with coronary heart disease in Chinese Han 
population. Arterioscler Thromb Vasc Biol 
2003a;23:328-34.  
 
Wang XY, Xue YM, Wen SJ, Zhang NL, Ji 
Z, Pan SY. The association of paraoxonase 
2 gene C311S variant with ischemic stroke 
in Chinese type 2 diabetes mellitus patients. 
Zhonghua Yi Xue Yi Chuan Xue Za Zhi 
2003b;20:215-9. 
 
EXCLI Journal 2010;9:159-172 – ISSN 1611-2156 
Received: October 15, 2010, accepted: November 23, 2010, published: November 26, 2010 
 
172 
Wheeler JG, Keavney BD, Watkins H, 
Collins R, Danesh J. Four paraoxonase gene 
polymorphisms in 11212 cases of coronary 
heart disease and 12786 controls: meta-
analysis of 43 studies. Lancet 2004;363: 
689-95. 
 
Wills AM, Cronin S, Slowik A, 
Kasperaviciute D, Van Es MA, Morahan 
JM, et al. A large-scale international meta-
analysis of paraoxonase gene polymor-
phisms in sporadic ALS. Neurology 2009; 
73:16-24. 
 
Wu BY, Liang HY, Chen DF, Liu L, Yang 
F, Hu HY, et al. Associations of Rsa I poly-
morphism at the 5' flanking region of 
CYP2E1 and PON2 148 polymorphism in 
neonates with preterm delivery. Chuan Xue 
Bao 2003;30:577-83. 
 
Xu HW, Yuan N, Zhao Z, Zhang L, Xia J, 
Zeng KM, et al. Study of the relationship 
between gene polymorphisms of paraoxo-
nase 2 and stroke in a Chinese population. 
Cerebrovasc Dis 2008;25:87-94. 
 
Yamada Y, Ando F, Niino N, Miki T, Shi-
mokata H. Association of polymorphisms 
of paraoxonase 1 and 2 genes, alone or in 
combination, with bone mineral density in 
community-dwelling Japanese. J Hum 
Genet 2003;48:469-75. 
